Metformin targets mitochondrial complex I to lower blood glucose levels

IF 12.5 1区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES Science Advances Pub Date : 2024-12-18 DOI:10.1126/sciadv.ads5466
Colleen R. Reczek, Ram P. Chakrabarty, Karis B. D’Alessandro, Zachary L. Sebo, Rogan A. Grant, Peng Gao, G. R. Scott Budinger, Navdeep S. Chandel
{"title":"Metformin targets mitochondrial complex I to lower blood glucose levels","authors":"Colleen R. Reczek,&nbsp;Ram P. Chakrabarty,&nbsp;Karis B. D’Alessandro,&nbsp;Zachary L. Sebo,&nbsp;Rogan A. Grant,&nbsp;Peng Gao,&nbsp;G. R. Scott Budinger,&nbsp;Navdeep S. Chandel","doi":"10.1126/sciadv.ads5466","DOIUrl":null,"url":null,"abstract":"<div >Metformin is among the most prescribed antidiabetic drugs, but the primary molecular mechanism by which metformin lowers blood glucose levels is unknown. Previous studies have proposed numerous mechanisms by which acute metformin lowers blood glucose, including the inhibition of mitochondrial complex I of the electron transport chain (ETC). Here, we used transgenic mice that globally express the <i>Saccharomyces cerevisiae</i> internal alternative NADH dehydrogenase (NDI1) protein to determine whether the glucose-lowering effect of acute oral administration of metformin requires inhibition of mitochondrial complex I of the ETC in vivo. NDI1 is a yeast NADH dehydrogenase enzyme that complements the loss of mammalian mitochondrial complex I electron transport function and is insensitive to pharmacologic mitochondrial complex I inhibitors including metformin. We demonstrate that NDI1 expression attenuates metformin’s ability to lower blood glucose levels under standard chow and high-fat diet conditions. Our results indicate that acute oral administration of metformin targets mitochondrial complex I to lower blood glucose.</div>","PeriodicalId":21609,"journal":{"name":"Science Advances","volume":"10 51","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.science.org/doi/reader/10.1126/sciadv.ads5466","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Advances","FirstCategoryId":"103","ListUrlMain":"https://www.science.org/doi/10.1126/sciadv.ads5466","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Metformin is among the most prescribed antidiabetic drugs, but the primary molecular mechanism by which metformin lowers blood glucose levels is unknown. Previous studies have proposed numerous mechanisms by which acute metformin lowers blood glucose, including the inhibition of mitochondrial complex I of the electron transport chain (ETC). Here, we used transgenic mice that globally express the Saccharomyces cerevisiae internal alternative NADH dehydrogenase (NDI1) protein to determine whether the glucose-lowering effect of acute oral administration of metformin requires inhibition of mitochondrial complex I of the ETC in vivo. NDI1 is a yeast NADH dehydrogenase enzyme that complements the loss of mammalian mitochondrial complex I electron transport function and is insensitive to pharmacologic mitochondrial complex I inhibitors including metformin. We demonstrate that NDI1 expression attenuates metformin’s ability to lower blood glucose levels under standard chow and high-fat diet conditions. Our results indicate that acute oral administration of metformin targets mitochondrial complex I to lower blood glucose.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
二甲双胍靶向线粒体复合物 I 降低血糖水平
二甲双胍是最常用的降糖药之一,但二甲双胍降低血糖水平的主要分子机制尚不清楚。先前的研究提出了急性二甲双胍降低血糖的多种机制,包括抑制电子传递链(ETC)的线粒体复合物I。在这里,我们使用转基因小鼠全局表达酿酒酵母内替代NADH脱氢酶(NDI1)蛋白,以确定急性口服二甲双胍的降血糖作用是否需要抑制ETC的线粒体复合体I。NDI1是一种酵母NADH脱氢酶,可以补充哺乳动物线粒体复合体I电子传递功能的缺失,对包括二甲双胍在内的线粒体复合体I药理学抑制剂不敏感。我们证明NDI1的表达减弱了二甲双胍在标准食物和高脂肪饮食条件下降低血糖水平的能力。我们的研究结果表明,急性口服二甲双胍靶向线粒体复合体I降低血糖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Science Advances
Science Advances 综合性期刊-综合性期刊
CiteScore
21.40
自引率
1.50%
发文量
1937
审稿时长
29 weeks
期刊介绍: Science Advances, an open-access journal by AAAS, publishes impactful research in diverse scientific areas. It aims for fair, fast, and expert peer review, providing freely accessible research to readers. Led by distinguished scientists, the journal supports AAAS's mission by extending Science magazine's capacity to identify and promote significant advances. Evolving digital publishing technologies play a crucial role in advancing AAAS's global mission for science communication and benefitting humankind.
期刊最新文献
Bioresorbable acoustic patch for simultaneous sealing and early detection of gastric leakage Enhancing biomedical optical volumetric imaging via self-supervised orthogonal learning Intracortical brain-computer interface for navigation in virtual reality in macaque monkeys Peaceful queen succession in the naked mole rat Imaging cell phone radiation in tissue mimics with hyperpolarized low-field MRI
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1